Reply to R. Glynne-Jones et al
D. Peiffert(Institut de Cancérologie de Lorraine), Michel Ducreux(Université Paris-Saclay), C. Lemanski, Thierry Conroy(Inserm), F. Mornex(Hôpital Lyon Sud), Christophe Hennequin(Inserm), L. Tournier-Rangeard(Délégation Centre-Est), Éric François(Centre Antoine Lacassagne), Olivier Bouché(CHU Dijon Bourgogne), Béata Juzyna(UniCancer Group), Jean-Michel Hannoun-Lévy(Centre Antoine Lacassagne), Marc Giovannini(Institut Paoli-Calmettes), Jean‐François Seitz(Aix-Marseille Université), Jean‐Pierre Gérard(Centre Antoine Lacassagne), Antoine Adenis(Centre Oscar Lambret), X. Mirabel(American Society of Clinical Oncology)
Cited by 0
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k